Switch to
More onapp

How to use scorecard? Learn more

Senores Pharmaceuticals Ltd

SENORES
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,315 cr, stock is ranked 1,066
Moderate RiskStock is 2.82x as volatile as Nifty
502.8528.35 (-5.34%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Bad

Insufficient Data

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,315 cr, stock is ranked 1,066
Moderate RiskStock is 2.82x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
PB RatioPB Ratio
9.99
Dividend YieldDiv. Yield
Sector PESector PE
50.72
Sector PBSector PB
6.57
Sector Div YldSctr Div Yld
0.53%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Senores Pharmaceuticals Ltd manufactures a range of pharmaceutical products, including tablets and APIs, focusing on international quality to meet global healthcare demands.

Financial TrendFinancial statements 

20222023202414.6339.02217.340.998.4231.44
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 20.90%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Analysts/Institutional Investor Meet/Con. Call Updates 
Announced OnJan 10, 2025

Senores Pharmaceuticals Limited has informed the Exchange about Schedule of meet | Download

Senores Pharmaceuticals Limited has informed the Exchange about Schedule of meet | Download

Board Meeting Intimation 
Announced OnJan 10, 2025

SENORES PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 23-Jan-2025 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended December 2024 and Other business. | Download

SENORES PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 23-Jan-2025 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended December 2024 and Other business. | Download

Press Release 
Announced OnJan 9, 2025

Senores Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 09, 2025, titled "Senores Pharmaceuticals receives ANDA approval for marketing MetoprololTartrate and Hydrochlorothiazide Tablet USP, 50 mg/25 mg and 100 mg/25 mg". | Download

Senores Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 09, 2025, titled "Senores Pharmaceuticals receives ANDA approval for marketing MetoprololTartrate and Hydrochlorothiazide Tablet USP, 50 mg/25 mg and 100 mg/25 mg". | Download

See all events